Apotex Health files preliminary prospectus for initial public offering of shares
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $1.44 a week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $5.77 plus GST every four weeks. After 52 weeks, price increases to the regular rate of $19.95 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
TORONTO – Apotex Health Corp. says it has filed a preliminary prospectus for an initial public offering that will see the Canadian generic drug company join the public market.
The Toronto-based company says the plan includes a treasury offering of shares and a secondary offering by certain shareholders, including SK Capital Partners, the company’s controlling shareholder.
Apotex says it has applied to list the shares on the Toronto Stock Exchange.
The number of shares to be offered and the price have not yet been determined.
Apotex has a broad portfolio of generic drugs and consumer health products.
It has operations in Canada, the U.S., Mexico and India.
This report by The Canadian Press was first published May 28, 2026.